208 related articles for article (PubMed ID: 15950799)
1. CT, RECIST, and malignant pleural mesothelioma.
Nowak AK
Lung Cancer; 2005 Jul; 49 Suppl 1():S37-40. PubMed ID: 15950799
[TBL] [Abstract][Full Text] [Related]
2. Assessment of tumor response in malignant pleural mesothelioma.
Ceresoli GL; Chiti A; Zucali PA; Cappuzzo F; De Vincenzo F; Cavina R; Rodari M; Poretti D; Lutman FR; Santoro A
Cancer Treat Rev; 2007 Oct; 33(6):533-41. PubMed ID: 17764849
[TBL] [Abstract][Full Text] [Related]
3. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).
Armato SG; Nowak AK
J Thorac Oncol; 2018 Jul; 13(7):1012-1021. PubMed ID: 29753121
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
Gudmundsson E; Labby Z; Straus CM; Sensakovic WF; Li F; Rose B; Cunliffe A; Kindler HL; Armato SG
Eur Radiol; 2019 Feb; 29(2):682-688. PubMed ID: 29967955
[TBL] [Abstract][Full Text] [Related]
5. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
van Klaveren RJ; Aerts JG; de Bruin H; Giaccone G; Manegold C; van Meerbeeck JP
Lung Cancer; 2004 Jan; 43(1):63-9. PubMed ID: 14698538
[TBL] [Abstract][Full Text] [Related]
6. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
Byrne MJ; Nowak AK
Ann Oncol; 2004 Feb; 15(2):257-60. PubMed ID: 14760119
[TBL] [Abstract][Full Text] [Related]
7. Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
Monetti F; Casanova S; Grasso A; Cafferata MA; Ardizzoni A; Neumaier CE
Lung Cancer; 2004 Jan; 43(1):71-4. PubMed ID: 14698539
[TBL] [Abstract][Full Text] [Related]
8. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria.
Tsao AS; Garland L; Redman M; Kernstine K; Gandara D; Marom EM
J Thorac Oncol; 2011 Mar; 6(3):598-601. PubMed ID: 21270668
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
Ak G; Metintas M; Metintas S; Yildirim H; Ozkan R; Ozden H
Eur J Radiol; 2010 Apr; 74(1):130-5. PubMed ID: 19268516
[TBL] [Abstract][Full Text] [Related]
10. Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study.
Buikhuisen WA; Qayyum F; Armato SG; Baas P
Lung Cancer; 2019 Dec; 138():139-140. PubMed ID: 31733933
[No Abstract] [Full Text] [Related]
11. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
Laurie SA; Hao D; Leighl NB; Goffin J; Khomani A; Gupta A; Addison CL; Bane A; Seely J; Filion ML; Pond GR; Levine MN
Lung Cancer; 2017 Feb; 104():65-69. PubMed ID: 28213002
[TBL] [Abstract][Full Text] [Related]
13. Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method.
Chen M; Helm E; Joshi N; Gleeson F; Brady M
Int J Comput Assist Radiol Surg; 2017 Apr; 12(4):529-538. PubMed ID: 28028655
[TBL] [Abstract][Full Text] [Related]
14. [Computed tomographic findings in diffuse malignant pleural mesothelioma].
Bohndorf K; Calavreszos A; Koschel G; Hüsselmann H; Hain E
Rofo; 1985 Sep; 143(3):279-84. PubMed ID: 2996064
[TBL] [Abstract][Full Text] [Related]
15. Malignant mesothelioma in an adolescent boy.
Varan A; Kara A; Haliloğlu M; Büyükpamukçu M; Ayhan A; Ruacan S
Pediatr Int; 1999 Dec; 41(6):693-5. PubMed ID: 10618893
[No Abstract] [Full Text] [Related]
16. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
Frauenfelder T; Tutic M; Weder W; Götti RP; Stahel RA; Seifert B; Opitz I
Eur Respir J; 2011 Jul; 38(1):162-8. PubMed ID: 21273389
[TBL] [Abstract][Full Text] [Related]
17. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
Laurie SA; Gupta A; Chu Q; Lee CW; Morzycki W; Feld R; Foo AH; Seely J; Goffin JR; Laberge F; Murray N; Rao S; Nicholas G; Laskin J; Reiman T; Sauciuc D; Seymour L
J Thorac Oncol; 2011 Nov; 6(11):1950-4. PubMed ID: 22005473
[TBL] [Abstract][Full Text] [Related]
18. Optimization of response classification criteria for patients with malignant pleural mesothelioma.
Labby ZE; Armato SG; Kindler HL; Dignam JJ; Hasani A; Nowak AK
J Thorac Oncol; 2012 Nov; 7(11):1728-34. PubMed ID: 23059782
[TBL] [Abstract][Full Text] [Related]
19. Computerized analysis of mesothelioma on CT scans.
Armato SG
Lung Cancer; 2005 Jul; 49 Suppl 1():S41-4. PubMed ID: 15950800
[TBL] [Abstract][Full Text] [Related]
20. Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions.
Armato SG; Nowak AK; Francis RJ; Kocherginsky M; Byrne MJ
J Thorac Oncol; 2014 Aug; 9(8):1187-94. PubMed ID: 25157772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
